Controlled Absorption of Statins in the Intestine

• US 20080260818A1
• Filed: 03/27/2006
• Published: 10/23/2008
• Est. Priority Date: 03/28/2005
• Status: Abandoned Application

• Current Assignee: Dexcel Pharma Technologies (Dexcel Limited)
• Original Assignee: Dexcel Pharma Technologies (Dexcel Limited)
• Inventors: Gomberg, Maxim, Penhasi, Adel, Ruderman, Marina
• Application Number:
  US11/909,961
• Publication Number:
  US 20080260818A1
• Time in Patent Office: Days
• US Class Current: 424/457
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet.

Claims

1-180. -180. (canceled)

181. A delayed onset slow release formulation for a statin and/or active forms of the statin, comprising:

a slowly disintegrating core comprising at least one statin, a filler and a release controlling agent, wherein the release controlling agent is present in a range of from about 5% to about 20% weight per weight relative to the total weight of the core, and a rate-controlling outer coating over the core, the rate-controlling outer coating selected from the group consisting of;

i) an outer coating featuring a mixture of cellulosic water insoluble polymers;

ii) an outer coating featuring a combination of a water insoluble polymer and a water soluble polymer;

iii) an outer coating featuring an enteric polymer coating;

iv) an outer coating featuring a polymer disintegrating at pH values above about pH 5;

v) an outer coating featuring a cellulosic polymer that is applied as a dry coating, the polymer forming a hydrogel;

vi) an outer coating featuring water insoluble hydrophilic particles embedded in a water insoluble flexible polymer, wherein the statin and/or active forms of the statin are released through diffusion through the water insoluble hydrophilic particles; and

vii) an outer coating featuring a dry coating or an enteric coating, with the proviso that the core does not comprise a disintegrating agent.

182. The formulation of claim 181, wherein the mixture of cellulosic water insoluble polymers comprises any two or more polymers selected from the group consisting of HPMC, EC, and microcrystalline cellulose.

183. The formulation of claim 181, wherein the combination of the water insoluble polymer and the water soluble polymer comprises a water insoluble polymer selected from the group consisting of a podimethylaminoethylacrylate/ethylmethacrylate copolymer, the copolymer being based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups, wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is approximately 1:

20, the polymer corresponding to USP/NF Ammonio Methacrylate Copolymer Type A, an ethylmethacrylate/chlorotrimethylammoniumethyl methacrylate copolymer, the copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1;

40, the polymer corresponding to USP/NF Ammonio Methacrylate Copolymer Type B, a dimethylaminoethylmethacrylate/methylmethacrylate and butylmethacrylate copolymer, a copolymer based on neutral methacrylic acid esters and dimethylaminoethyl methacrylate esters wherein the polymer is cationic in the presence of acids, an ethylacrylate and methylacrylate/ethylmethacrylate and methyl methylacrylate copolymer, the copolymer being a neutral copolymer based on neutral methacrylic acid and acrylic acid esters, ethylcellulose, shellac, zein, and waxes, paraffin, cellulose acetate, cellulose propionate, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly (methyl methacrylate), poly(ethylmethacrylate), poly (butyl methacrylate), poly (isobutyl methacrylate), and poly (hexyl methacrylate), poly (isodecyl methacrylate), poly(lauryl methacrylate), poly (phenyl methacrylate), poly (methylacrylate), poly (isopropyl acrylate), poly (isobutyl acrylate) poly(octadecyl acrylate), poly (ethylene), poly (ethylene) low density, poly(ethylene) high density, poly (ethylene oxide), poly (ethyleneterephthalate), poly (vinyl isobutyl ether), poly (vinyl acetate), poly(vinyl chloride) and polyurethane, or mixtures thereof.

184. The formulation of claim 183, wherein the water insoluble polymer comprises ethylcellulose.

185. The formulation of claim 181, wherein the water soluble polymer comprises polyvinyl alcohol, polyvinylpyrrolidone (PVP), copolyvidone, methylcellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose, polyethylene glycol, carboxymethyl cellulose (sodium salt), hydroxyethyl cellulose, a water soluble gum, polysaccharide and/or mixtures thereof.

186. The formulation of claim 185, wherein the water soluble polymer comprises copolyvidone.

187. The formulation of claim 181, wherein the enteric polymer coating comprises a polymer selected from the group consisting of cellulose acetate phthalate, hydroxy propyl methyl cellulose acetate succinate, poly(methacrylic acid, methyl methacrylate)1:

1 and (Eudragit L100), poly(methacrylic acid, ethyl acrylate)1;

1 (Eudragit L30D-55).

188. The formulation of claim 187, wherein the polymer comprises HPMC AS.

189. The formulation of claim 181, wherein the cellulosic polymer of the dry coating comprises HPMC K 15 M, or wherein the water insoluble flexible polymer comprises a methacrylic polymer.

190. The formulation of claim 189, wherein the methacrylic polymer comprises Eudragit E.

191. The formulation of claim 189, wherein the water insoluble hydrophilic particles comprise a polymer forming a hydrogel upon contact with liquid, the polymer being selected from the group consisting of poly(hydrox alkyl methacrylate);

kappa-carrageenan;

polyvinylpyrrolidone;

anionic and cationic hydrogels;

polyelectrolyte complexes;

poly(vinyl alcohol) having low amounts of acetate, cross-linked with glyoxal, formaldehyde, or glutaraldehyde;

a mixture comprising methyl cellulose, cross-linked agar and carboxymethyl cellulose;

a water-insoluble, water-swellable copolymer produced by forming a dispersion of finely divided maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene;

water-swellable polymers of N-vinyl lactams;

polysaccharide, water swellable gums, high viscosity hydroxylpropylmethyl cellulose or mixtures thereof.

192. The formulation of claim 191, wherein the water insoluble polymer is calcium pectinate or microcrystalline cellulose.

193. The formulation of claim 181, wherein the filler is present in an amount ranging from about 10% to about 85% (W/W) relative to the total weight of core, and is selected from the group consisting of starch, lactitol, lactose, an inorganic calcium salt, microcrystalline cellulose, sucrose, and combinations thereof.

194. The formulation of claim 193, wherein the microcrystalline cellulose has a particle size of less than about 100 microns.

195. The formulation of claim 181, wherein the release controlling agent comprises a water insoluble, hydrophilic swellable polymer selected from the group consisting of poly(hydrox alkyl methacrylate);

kappa-carrageenan;

polyvinylpyrrolidone;

anionic and cationic hydrogels;

polyelectrolyte complexes;

poly(vinyl alcohol) having low amounts of acetate, cross-linked with glyoxal, formaldehyde, or glutaraldehyde;

a mixture comprising methyl cellulose, cross-linked agar and carboxymethyl cellulose;

a water-insoluble, water-swellable copolymer produced by forming a dispersion of finely divided maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene;

water-swellable polymers of N-vinyl lactams;

polysaccharide, water swellable gums, high viscosity hydroxylpropylmethyl cellulose and mixtures thereof.

201. The formulation of claim 187, selected from:

a) a formulation that preferentially releases statin in the intestine of the subject;

b) a formulation that preferentially release statin in the lower gastrointestinal tract; and

c) a formulation that preferentially releases statin in the colon of the subject.

209. A method for using a formulation according to claim 181 to reduce stress on the liver of the subject treated by at least one other drug involved in the liver metabolism, to reduce stress on the liver of the subject, to reduce liver side effects including increased level of transaminases, to reduce muscle pain and level of CPK, to reduce gastrointestinal effects comprising nausea, dyspepsia, flatulence and constipation, or for providing treatment for high blood cholesterol to a subject in need thereof.

211. A method for using a formulation according to claim 181, for providing release of the statin or the pharmaceutically acceptable salt or ester or active form thereof that is not affected by food.

213. A method for providing a therapeutically effective amount of a statin or a pharmaceutically acceptable salt or ester or active form thereof to a subject, comprising administering orally to the subject a formulation according to claim 181.

196. A delayed onset controlled release formulation for providing an increased bioavailability as measured by AUC of a statin and/or active forms of the statin, relative to that resulting from the administration of an equivalent dose of the conventional immediate release formulations, comprising:

a slowly disintegrating core comprising at least one statin and at least one release controlling agent and a rate-controlling outer coating over the core, providing controlled release.

197. The formulation of claim 196, wherein the release controlling agent comprises a material selected from the group consisting of a suitable hydrophilic cellulosic gelling polymer;

vinyl polymers;

acrylic polymers and copolymers, natural and synthetic gums, gelatin, collagen, proteins, polysaccharides; and

mixtures thereof.

198. The formulation of claim 197, wherein the polysaccharide in the release controlling agent comprises a cross-linked polysaccharide selected from the group consisting of insoluble metal salts or cross-linked derivatives of alginate, pectin, xantham gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof, or wherein the cellulosic polymer comprises a modified cellulose selected from the group consisting of cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose.

199. The formulation of claim 197, wherein the cellulosic gelling polymer comprises a material selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose;

or wherein the vinyl polymer is selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, and the like.

200. The formulation of claim 197 wherein the acrylic polymers and copolymers are selected from the group consisting of acrylic acid polymer, methacrylic acid copolymers, ethyl acrylate-methyl methacrylate copolymers;

or wherein the natural and synthetic gums are selected from the group consisting of guar gum, arabic gum, xanthan gum;

or wherein the polysaccharides are selected from the group consisting of pectin, pectic acid, alginic acid, sodium alginate, polyaminoacids, polyalcohols and polyglycols.

202. The formulation of claims 196, wherein the core is in the form of one of a tablet, pellets, microparticles, agglomerate, and capsule.

203. The formulation of claim 196, wherein the release controlling agent is present in an amount ranging from about 5% to about 20% weight per weight of the core.

204. The formulation of claim 196, wherein the core further comprises at least one of a filler, an absorption enhancer, a binder, a disintegrant, a hardness enhancing agent, a stabilizer, a flow regulating agent, a lubricant, an antioxidant, a chelating agent, a sequestrate and a wicking agent.

205. The formulation of claim 196, wherein the coating comprises at least one of the following:

a. pH dependent polymer

b. a combination of at least one water soluble polymer and at least one water insoluble polymer

c. a combination of at least one swellable polymer and at least one water insoluble polymer

d. a combination of at least a water soluble pore forming agent and at least one water insoluble polymer

e. at least one swellable gel forming polymer

g. an erodible composition

h. a combination of at least one pH dependent polymer and at least one water insoluble polymer

207. The formulation of claim 196, wherein the formulation releases substantially no statin in vitro for at least about 2 to about 6 hours.

208. The formulation of claim 196, wherein the statin is selected from the group comprising simvastatin, beta-hydroxy acid simvastatin, lovastatin, mevastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rivastatin and cerivastatin, or pharmaceutically acceptable salts and esters thereof.

210. A method for using a formulation according to claim 196, to reduce stress on the liver of the subject treated by at least one other drug involved in the liver metabolism, to reduce stress on the liver of the subject, to reduce liver side effects including increased level of transaminases, to reduce muscle pain and level of CPK, to reduce gastrointestinal effects comprising nausea, dyspepsia, flatulence and constipation, or for providing treatment for high blood cholesterol to a subject in need thereof.

212. A method for using a formulation according to claim 196, for providing release of the statin or the pharmaceutically acceptable salt or ester or active form thereof that is not affected by food.

214. A method for providing a therapeutically effective amount of a statin or a pharmaceutically acceptable salt or ester or active form thereof to a subject, comprising administering orally to the subject a formulation according to claim 196.

216. A delayed onset controlled release formulation according to claim 196 that releases a statin and/or a pharmaceutically acceptable salt and/or ester thereof in the lower gastrointestinal tract of a subject, characterized in that the in vivo blood plasma concentration of the statin and/or a pharmaceutically acceptable salt and/or ester thereof is substantially zero for at least about one hour after oral administration and is controlled by the lag time, providing an increased bioavailability of a statin and/or active forms of the statin, as measured by AUC relative to that resulting from the administration of an equivalent dose of the conventional immediate release formulations.

217. The formulation of claim 216,

wherein the in vivo blood plasma concentration is extended at least 24 hours, or

wherein the core comprises a dose of statin of no more than about one-half of a dose as compared to a corresponding immediate release formulation, but wherein a level of at least one statin active form after administration of the delayed controlled release formulation is at least about a level of the active metabolite after administration of the corresponding immediate release formulation, or

wherein the core comprises a dose of statin of no more than about one-half of a dose in the corresponding immediate release formulation, but wherein a level of at least one statin active metabolite after administration of the controlled release formulation is at least about a level of the active metabolite after administration of the corresponding immediate release formulation.

215. A method for providing enhanced bioavailability of a statin or pharmaceutically acceptable salts or esters thereof or its related metabolite in a subject, or for providing an increased amount of a statin or a pharmaceutically acceptable salt or ester thereof, relative to that resulting from the administration of an equivalent dose of the conventional immediate release formulations, comprising:

administering orally to the subject a delayed onset controlled release formulation comprising a core and an outer coating that surrounds the core;

the core comprising a statin, or a pharmaceutically acceptable salt thereof and at least one release controlling agent, and

the coating characterized by at least one of

a. pH dependent coating film, preferably an enteric coating

b. a combination of at least one water soluble polymer and at least one water insoluble polymer

c. a combination of at least one swellable polymer and at least one water insoluble polymer

d. a combination of at least a water soluble pore forming agent and at least one water insoluble polymer

e. at least one swellable gel forming polymer

f. at least one erodible polymer

g. a combination of at least one pH dependent polymer and at least one water insoluble polymer

h. a two-layer coating comprising a rupturable outer layer and swellable inner layer wherein the in vivo blood plasma concentration of the statin is substantially zero for at least about two hours after oral administration.

218. A method for providing enhanced bioavailability of statin and/or a pharmaceutically acceptable salts and/or esters thereof and/or its related metabolite in a subject, comprising:

administering orally to the subject a controlled release formulation excluding delayed burst release and delayed immediate or fast release characterized in that the in vivo blood plasma concentration of the statin is substantially zero for at least about one hour after oral administration.

219. A controlled release method for providing an increased amount of a statin and/or active forms of the statin circulating in the blood of a subject, relative to that resulting from the administration of an equivalent dose of a conventional immediate release formulation to the subject, wherein the method excludes delayed burst release and delayed immediate or fast release.